Live Chat

تداول BioNTech BNTX

البيع
 شراء

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
date إغلاق change معدل التغيير (%) instr__open مرتفع منخفض

Markets.com news

bitcoin dropping
Antonio Ferlito 2024 Aug 19, 16:05

Test News Article Arabic Only

CFD Trading BoE
French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

الأسبوع القادم: نتائج الانتخابات الفرنسية هامة بالنسبة للأسواق الأوروبية

الفوركس المؤشرات
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

الأسبوع القادم: هل تتسبب فرنسا في أزمة جديدة لليورو؟

CPI
RBA, SNB, Bank of England rate decisions due next week
markets.com Support Team 2024 Jun 13, 21:00

الأسبوع القادم: البنك الأسترالي، البنك البريطاني.. الثبات أم التغيير؟

الفوركس المؤشرات

معلومات

الفارق الهامشي

0.9949

الهامش (%)

0.8754 %

الرافعة المالية

1:10

فائدة الشراء بين ليلة وضحاها

-0.0597 %

فائدة البيع بين ليلة وضحاها

-0.0292 %

عملة

USD

ساعات التداول

السوق مغلق

الثلاثاء

14:31 - 20:59

الاثنين

14:31-20:59

الأربعاء

14:31-20:59

الخميس

14:31-20:59

الجمعة

14:31-20:59

instr__analysis_statistics

instr__open

---

instr__close

---

instr__52week_range

--- – ---

instr__market_cap

27212888064

instr__shares_outstand

239740000

instr__earnings_date

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

instr__eps

-2.01

instrument_learn_more

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

related_instruments

الأصل
البيع
شراء
معدل التغيير (%)

تداول الآن

تداول الآن

تداول الآن

تداول الآن
view_all_instruments
Trustpilot
Live Chat